tailieunhanh - Báo cáo khoa học: "Large volume unresectable locally advanced nonsmall cell lung cancer: acute toxicity and initial outcome results with rapid arc"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Large volume unresectable locally advanced nonsmall cell lung cancer: acute toxicity and initial outcome results with rapid arc. | Scorsetti et al. Radiation Oncology 2010 5 94 http content 5 1 94 RADIATION ONCOLOGY RESEARCH Open Access Large volume unresectable locally advanced nonsmall cell lung cancer acute toxicity and initial outcome results with rapid arc 1 1 1 1 1 2 Marta Scorsetti Pierina Navarria Pietro Mancosu Filippo Alongi Simona Castiglioni Raffaele Cavina Luca Cozzi3 Antonella Fogliata3 Sara Pentimalli1 Angelo Tozzi1 Armando Santoro3 Abstract Background To report acute toxicity initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer stage III with volumetric modulated arcs using RapidArc RA . Methods Twenty-four consecutive patients were treated with RA. All showed locally advanced non-small cell lung cancer with stage IIIA-IIIB and with large volumes GTV 299 175 cm3 PTV 818 206 cm3 . Dose prescription was 66Gy in 33 fractions to mean PTV. Delivery was performed with two partial arcs with a 6 MV photon beam. Results From a dosimetric point of view RA allowed us to respect most planning objectives on target volumes and organs at risk. In particular for GTV D1 D99 D5 -D95 contralateral lung mean dose resulted in for spinal cord D1 for heart V45Gy for esophagus D1 . Delivery time was 133 7s. At three months partial remission 50 was observed in 56 of patients. Acute toxicities at 3 months showed 91 with grade 1 and 9 with grade 2 esophageal toxicity 18 presented grade 1 and 9 with grade 2 pneumonia no grade 3 acute toxicity was observed. The short follow-up does not allow assessment of local control and progression free survival. Conclusions RA proved to be a safe and advantageous treatment modality for NSCLC with large volumes. Long term observation of patients is needed to assess outcome and late toxicity. Background Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer NSCLC account for at least .